Latest / Powering the Future Within / Episode 13: Can Neurotech Cure Epilepsy? with Mayo Clinic Neurosurgeon Dr. Jonathon Parker
Transcript
- speaker-0: Welcome to Powering the Future Within, the podcast where we explore the breakthroughs shaping the future of MedTech. I'm Omari Bachnight, CEO of ResonantLink Medical. Each episode we speak with a leader who is driving the next wave of medical innovation, advancing technologies that are smarter, less invasive, and more connected than ever before. This is where the future of health takes shape. Let's dive in. Today's guest is Dr. Jonathan Parker. Dr. Parker is an epilepsy and functional neurosurgeon who serves as the director of the device-based neuroelectronics lab at Mayo Clinic in Arizona. Dr. Parker specializes in treating complex neurological conditions such as epilepsy, as well as movement and psychiatric disorders. He leverages minimally invasive surgical techniques and And advanced neuromodulation technologies. As the director of a device-based neuroelectronics lab, he's helping push forward the next generation of implantable therapies, including brain machine interfaces. What makes his work particularly exciting is that it sits right at the frontier of where biology meets engineering. Jonathan, welcome to Powering the Future Within. speaker-1: Thanks, Amari, for that introduction. Looking forward to our conversation today. speaker-0: Likewise, this is really, really exciting and and I'm looking forward to it as well. So you have a very interesting clinical background, first pursuing your PhD in cancer biology before pursuing your MD and training in neurosurgery. How has that shaped how you think about neurosurgery? speaker-1: Well, I've always been interested in in sort of figuring things out, if you will, ⁓ even from an early age, using observation to understand the outside world, ⁓ and and figuring out what tools you need to describe the world, ⁓ what quantitative tools, math, biology, et cetera. So I came to things with that lens from an undergraduate education in biology and computer science, ⁓ was deciding between medical school and graduate school and decided to do both through a medical scientist training program. ⁓ and I would say my trajectory was sort of set ⁓ for launch in in meeting someone, a specific neurosurgeon scientist who I ended up doing my my PhD with Alan Waziri, who really showed me the power of combining ⁓ a very cutting edge clinical skill set in a scientific mind to address the pressing challenges in neuro oncology, ⁓ which I was working on at the time. And then how do you how do you blend that ⁓ in in the atmosphere of a clinical practice? in do that in a in a sort of a sustainable fashion. So that that's what got me started in in this trajectory. speaker-0: Yeah, and it seems like in in the particular space of neuro neuro oncology, having that very analytical approach, scientific approach, would pay massive dividends just in terms of how you think about some of these very complex conditions. speaker-1: I definitely agree with that. And and as we know from the last, you know, decades of research on glioblastoma, one of the most common malignant brain tumors, we've really struggled to move the needle. and we did some innovative work in trying to actually culture human brain tumors outside the body, not in dissociated cultures, but actually as whole tissue slices. And and that was sort of a ⁓ one of the first ⁓ demonstrations of that in the field to take a little bit of an innovative approach to better model the system. That's now been taken on by other research labs across the country and across the world. And maybe one of the things that drove me in this transition from neurooncology research to neuro ⁓ sort of more neurosciences and epilepsy and neuromodulation was just the emerging set of tools that we had in neuromodulation to change how the brain functions, to change how neural circuits function, sort of a more of a read-write than we had in the oncology space. And I think that's what attracted me to that that pivot into that area. speaker-0: Interesting. So let's let's talk more about that concept of neuromodulation and the the concept of read write. How do you describe it to patients? 'Cause I can imagine ⁓ talking about reading and writing writing the brain might come with complications. speaker-1: Yeah, you know, that that happens further on in the conversation. The most, you know, important part of the interaction is really low-tech. You know, what what is the disease that's facing the patient? How is it affecting them their day-to-day? What are they stopped from doing that they want to do that brings them joy in life and accomplishment, satisfaction? So you you gotta figure that out first before all the explanations and and whatnot. Once you understand what the process is, what the impact is. You can sort out as a, you know, any clinician, but specifically a surgeon, do you have the skill set, technologies, and strategies to address the combination of the disease and what their expectation is and what they want to do? So I that's sort of how I start. A lot of times that's with an epilepsy patient, the fact they're having severe seizures just by medication. For an essential tremor patient, that's they've been having medication for years and years, but now they can't eat and drink or write or knit or do the hobbies that they like to do. So we we start there. And if the therapy and the appropriate therapy is neuromodulation, then we get into more of the details and talk about how these neural circuits are disrupted, how devices either on the surface of the brain or in the brain can then repair or rehabilitate these circuits. And like anything in life, we we we we start ⁓ general and then we get specific. And there's certainly folks like engineers with these conditions who want a lot a lot more details and we can go we can go down to the molecular and neuronal level there. But at the end of the day, most of the people want to know what's the what's the reliability, what's the predictability of the result, and what's the safety? And will it get me back to what I wanna do? And and that's what we focus on. speaker-0: Yeah. Yeah, those base elements seem like they cut across all all therapies. So it's it's great that you kind of start and end there. I'm curious, with a lot of the neuromodulation approaches within neuroscience, a lot of it isn't at the stage where it's quote unquote curative. However, the improvement over baseline, the improvement over where you first meet patients can be substantial, sometimes subjective yet substantial. Is there a a way that you would characterize expectations knowing that rarely will it be fully curative. speaker-1: Yeah. So that I I and getting back to sort of the what we were just talking about, how is the disease impacting their life? So with the knowledge that as you as you pointed out, depending on the condition that neuromodulation may be palliative, sometimes I use the term as turning down the volume on the symptoms, decreasing the severity. And then I start with that and also point out that depending on the disease process, ⁓ a young patient with epilepsy may be expected to live for this for the next ⁓ sixty years longer. If it's an older patient with a central tremor, maybe a a a shorter time horizon. But what I try to describe is if you turn the volume down on a symptom and you're living many more years with just reduced severity of the symptom, it translates over the long run to just improved quality of life. you know, the mathematicians like to call this the area under the curve phenomenon, right? Is that if you change the slope of the line, right, you're gonna you're gonna live so many more years with just less burden. From the symptom that's coming from the disease. So I try to focus on that. We also know that different conditions progress differently. A Parkinson's patient tends to progress over time. We we know that DBS is not disease modifying and changing the overall molecular and cellular underpinnings, but it certainly does decrease the severity and volume of those symptoms. And everyone progresses differently. So the effects that you see might be different from patient to patient. So patients need to know that to have a realistic expectation. ⁓ about what the therapy can do for them. speaker-0: And he used the acronym DBS, which is deep brain stimulation. speaker-1: That's correct. speaker-0: Fantastic. So when you started your your training and and you make this evolution moving from neuro oncology to broader neuroscience, did you at that time envision that there could be so many applications for neuromodulation? Because it just seems like it's exploding over the last ten years. speaker-1: Yeah. W well when I made that transition, you know, the technology ⁓ was advancing. You know, basically the devices that we had at our disposal were vagus nerve stimulators, responsive neurostimulators, and deep brain stimulators. I sometimes refer to this affectionately as the alphabet soup of neuromodulation, your your VNS, your RNS, and your DBS. in the really the focus there had been for epilepsy. ⁓ for VNS and RNS and then movement disorders and just then emerging into epilepsy at that time that I was getting into the field for DBS or deep brain stimulation. Now we see, you know, ⁓ a real explosion ⁓ of interest in new clinical trials for responsive neurostimulation therapies for things like loss of control eating disorder, which is, you know, Casey Halpern's work that I was part of as a resident trainee, to ⁓ post-traumatic stress syndrome to chronic pain. Now with a renewed interest in deep brain stimulation for treatment refractory depression. so that there has been an explosion of research. Those new indications in terms of the you know, registered FDA new indications, those have been slower to emerge for our field. And that's one of the things that we need to focus on is actually getting these therapies across the line from small first in human early feasibility studies now into FDA approved. predictable, deliverable, scalable neuromodules modulation solutions. I think I'm optimistic that's the phase that we're in now. ⁓ but on the pay with the pay putting on a patient hat, I want that to go quicker and deliver these ⁓ therapies to patients when they're safe and effective. speaker-0: Yeah. And as you look at designing these clinical trials, you characterize this concept of reduction of the burden of disease, or as you say, reducing the volume, which is a really great metaphor, I think, for a lot of these treatments. And when you reduce the volume to a certain level, it can kind of fade to the background and patients can get back to life, which is great. But when you think about historical clinical trials, a lot of them were driven by very hard endpoints. Are you finding receptivity in clinical trial design to the notion of we're looking at reduction of burden of disease as a very meaningful endpoint for some of these treatments? speaker-1: Think that there is general interest in that ⁓ from both regulatory and ⁓ agencies and also from the patient side, patient advocacy groups, et cetera. If you take the brain computer interface space for, let's say, ALS or spinal cord injury, you know, the the ⁓ the end effector, right, might be running a robotic arm, it may be generating a synthetic voice, it may be running a cursor. There's such a a wide space of potential uses in terms of. re-engaging in normal life, it's hard to capture that in a single solitary endpoint. So in those studies, there's been more of a focus on impact of quality of life, caregiver burden, et cetera. So I think I think that is now coming around in especially the brain computer interface trials for those conditions that we just talked about. But for epilepsy and movement disorders, we we've had more ⁓ sort of single scale outputs, things like the UP of DRS, which is specific motor scale for Parkinson's disease. For epilepsy, we're still, I think, unfortunately, a little hung up on just seizure frequency reduction, even though at first glance that seems like what we should focus on. ⁓ a lot of patients just can't track their seizures. ⁓ and we don't have objective seizure counts ⁓ in in the majority of clinical trials for novel epilepsy therapeutics. That's a big problem there. And epilepsy, we know also affects cognition, memory. Those are typically secondary endpoints in a lot of these trials. But when you talk to patients, it's the predictability of preventing seizures and and in that neurocognitive impact that's the most important. speaker-0: Right. And let's dive into epilepsy a little bit more. Why is this condition so difficult to manage to begin with? speaker-1: Well, thankfully for for our patients, about two thirds of them are well controlled and act actually have no seizures on medications. So surgery and devices are certainly not required or are are appropriate for everyone with epilepsy. But for up to a third of patients, the medications fail the patient. The the seizures continue, they persist, they become what we call a drug resistant epilepsy patient. And in those patients, you know, in years past, we really had limited tools. ⁓ our tools are mainly focused on localizing the onset and open large neurosurgical procedures to to very carefully as we can remove that area of the brain. And it's just been now in the last two decades that we have the neuromodulation opt-ins and VNS, DBS, and RNS. It still is though a a a truism, generally speaking, that s open surgery, even though it's more invasive, has a much higher rate and is really the only therapy that can reliably make patients seizure free. Expanding on that theme we just talked about, the other devices, VNS, the DBS, the RNS, turn the volume down, less seizure frequency, some improvement in those neurocognitive measures, but it's certainly not a cure. So our research lab ⁓ here at the Mayo Clinic is really focused on are there ways that we can actually turn those neuromodulation therapies into curative therapies? And and we have some ideas about how we can do that, biomarkers, pattern specific neuromodulation that's tailored to individuals. So we're optimistic to the for that future, even the combination of specific medications and neuromodulation. Can we use those together to get the patient to seizure freedom? speaker-0: One of the truisms in interventions is typically that you can obtain better efficacy by getting more directly to the condition. In other words, operating in a more open environment. And that's sort of what you're describing. But the direction you're heading in seems to be adopting minimally invasive techniques that can replicate open eff open surgical efficacy. Is that kind of the direction you're headed in? speaker-1: I think that's a that's an interesting way to to frame it. ⁓ what I would say is that I think some of the biggest successes in epilepsy surgery are when there's a very focal or regional onset or what we what we like to call a lesion or something abnormal we see on imaging. And we can map that sometimes from wires on the surface of the brain or in the brain, and we can cut that out. But a lot of the patients we see have a completely normal MRI, or they may even have Epilepsy and seizure starting from multiple brain regions. So the question of directly interfacing with the organ becomes more complex if the if the surface of interface is the whole brain, right? Or is multiple regions of the brain. So I think for a organ that is so complex in both its functional and spatial domains, the convolutions, right? We've all heard it, you spread out all the convolutions of the brain, right? It it covers an enormous surface area because of all the gyri and sulci. These are the GM, you know, the the the waypoints of the geometry and the geography, right, of the brain surface. How do we interface with every last square millimeter of that? We don't have a platform to do that yet. So that's why, you know, drugs, you think, well, if you can at least get it across the blood-brain barrier, you can get it to that geography equally. But for brain computer interface, we're really just Exploring that space right now. We're getting better and better at interfacing with very small brain regions at high resolution. However, typically, at least with the tools we have now, that's still fairly invasive, although we're getting better, robotics, small nanowires and microwires in the brain. ⁓ however, there are ways that we can deliver neur neuromodulation non invasively to affect that geography, which may be able to be a subscalp device or a device mounted in the skull. That doesn't have to penetrate the brain tissue. So we're very much still in the phase of sorting out the science there. And now we now have first generation devices actually to do all those three things I just talked about: microwires in the brain, devices in the subscalp and skull space, ⁓ and then continued work with the workhorse, which is DBS or actually wires in the brain tissue. speaker-0: Yeah. It it strikes me that there's a continuing conversation within the brain computer interface community and simplifying it essentially you have one camp that talks about more coverage, more electrodes, better computation, essentially better resolution across the brain. And then another another group that sort of focuses more on let's be as minimally invasive as possible. And it'll be really interesting to see how those two play out. But it strikes me that your work is almost a hybrid of both and trying to find that intersection to optimize efficacy versus safety for the benefit of patients. speaker-1: Yeah, and I I I have a I think a a really interesting way to think about that. And I I think both of those bookings that you described can and should exist and sustain into the future. And I think I can hopefully describe why. So when you think about what you want to do with the brain computer interface, if you want to do something very complex like run a multi ⁓ a multi jointed robot arm or generate ⁓ very fluent speech or synthetic voice, then the likelihood in terms of the information Or the data or the data rate that you need to do that is very high, at least in what we think now. Typically that means that you need to have recording sites from the brain that carry separate information to get enough variable information then to drive those high complexity systems. However, if you need to do something simple, which is a move a cursor in one direction or click, for example. People have ⁓ I didn't coin this, but the brain click, right? Is a is a concept that people have talked about. ⁓ or maybe even just record a biomarker that guides deep brain stimulation, the amount of information that you need may be less. So the spatial scale that you record from may be broader in the brain, and it may be able to be a non-invasive or minimally invasive device. So I think those are the bookends. What do you need to do to treat the disease? And what's engineer and design the device. to meet that application, always with the guiding principle, the most minimally invasive device to meet the clinical need. Right. That should be our guiding principle. ⁓ and that's how I look at the field. speaker-0: Yeah, I like that the most minimally invasive device to meet the meet the need. And we use these terms to describe conditions, but in of themselves they're often hyper heterogeneous. So, you know, how epilepsy manifests in one patient could be completely different than in another, ⁓ which might require different approaches depending upon how it manifests in that particular patient, which is one of the reasons why sometimes people describe the concept of closed loop therapy as being sort of a holy grail. And when we talk about closed loop, we're really talking about targeting a biomarker or biomarkers to inform how the technology adapts for treatment, almost like individualized or personalized technology. Where in your your framework does closed loop come into play and is it something that you're excited about in principle? speaker-1: It's definitely something I'm excited about. But I think if we sort of extrapolate from the paradox of in the promise of precision medicine, right? This concept we were going to understand the genome and the transcriptome, the secretome, and be able to dial that into a patient specific therapy, ⁓ has had, you know, some successes in various domains, but it's really been hard to generalize and to scale. And now we have a lot of ⁓ biomarker tests that are helping us do that. But I think when we try to extrapolate that to neuromodulation and we think about personalized therapy, we have to think about the variability. What's the bio? We got to go back to the biology. What's the driver of that? Is it that there's different geographies of the brain involved? If it's a personalized therapy that involves different brain geographies, then there's inherent limitations in the fact that we pretty much implant devices in a small subset of brain regions, right? And once you start to have to do that. Differently for every single patient, that's hard. That that's a challenge. ⁓ and that's sort of one of the things that we've encountered with the RNS device. When we have to do regional neuromodulation, every implant is different. So it makes it hard for us as a field to learn and to optimize the therapy. So when we optimize closed loop therapy, if these are changes in the disease pathophysiology that are in what I like to call the time domain, varying over time or brain state, then I think we can start to think about how closed loop therapy can be useful because We may need different types of neuromodulation at certain times. If we need different types of neuromodulation across time and space, meaning different brain sites, that's when the complexity becomes cumbersome. And ⁓ so I think right now we've very much focused on the time domain of closed loop neuromodulation. speaker-0: If you were to contrast this with your background in neuro oncology and oncology even more broadly speaking, oncology is a field where precision-based therapies ⁓ have really produced some really positive outcomes and really strong advances. And that seems to be more based off of ability to diagnose with better fidelity. ⁓ this seems to be different, or are there ways where that background in oncology and and their ability to sort of tailor therapies is something that gives you some insights on the neuroscience side? speaker-1: Yeah, I think it's appealing to use that process and and try to port that over to neuromodulation to understand these patients that have really profound impacts from neuromodulation. For instance, if you take DBS for epilepsy, there's about three to five percent of people that are actually disease-free with that condition. ⁓ and we still don't fully understand that. When we look at, you know, ⁓ drug trials, small molecule inhibitor trials. Oftentimes I think we had some early wins there with these outlier patients that we saw. Okay, they had a specific gene mutation. We we lear we we ⁓ we lock that in, we can have a companion diagnostic, we can target that drug to that gene mutation and that tumor ⁓ or that expression marker, and then we carry that forward. I think we've lagged behind a little bit of in that space in neuromodulation because the currency, at least so far, the focus has not been understanding patients underlying. genome for the efficacy of neuromodulation, although I think we could have a whole sidebar on that. But we've been really looking at the brain signals. Can the patient's brain signals or MRI predict? And there's certainly some good case examples, right? Like in DBS, we know more or less for movement disorder, ⁓ where to put these contacts in the brain to get the best result. We know when you're out of that bubble, so to speak, the quality of the therapy degrades. We have a little bit of that signal on epilepsy, although the story is still being told. But outside of the spatial domain of where these wires go in the brain, predicting sort of a priori, even before the device goes in, which patients are gonna have the best outcome based off a scalp EG metric, et cetera, that I think is lagged behind. ⁓ there's some companies that are doing that, I think, effectively now in the pharma space for depression and other psychiatric conditions, using EEG biomarkers to stratify patients in clinical trials. We're not quite there yet for neuromod ⁓ devices, but I think that's the direction that is ⁓ Appealing for us to head as a field. speaker-0: Yeah. And for devices for epilepsy, ⁓ in many cases where we are talking about brain surgery, I'm curious, you're taking a patient population that's drug resistant, so still having seizures, which can cause a lot of fear. And now we're looking at talking to them about brain surgery, which obviously people start to think about the invasiveness of that. How do you walk a patient through the thought process of moving potentially from one fear to to another. speaker-1: Well, I think it's important to understand ⁓ as deeply as we can, you know, it it sounds sort of you know old adage, you know, try to walk a mile in their shoes and and that's hard, right? We don't have the condition, but talking with patients, understand what's the root cause of the fear. And in in my experience and the time I've done this with epilepsy patients, there's a couple root causes. ⁓ one is ⁓ you know, the unknown, but being more precise, the unpredictability of the unknown. When will this event happen? Will it be when I'm talking with my best friend? Will it be out when I'm on a first date, when I'm making an important work conversation? That part, that unpredictability is really bad for patients. And it weighs heavily on the patients in the in their in even in their good moments. So I think that's key. Another is for a disease like epilepsy is, you know, the the stigma and societal ⁓ a component of that. How will my loved ones and friends and family member, the general public think of think of this. And lastly, too, is that maybe the old, you know, the ultimate fear is death. We know that there's this this rare complication of epilepsy called SUDEP or sudden unexplained death in epilepsy, where ⁓ with ⁓ basically no warning, a single seizure ⁓ causes a cardiac or respiratory arrest ⁓ and leads to the patient's death. So those three things weigh heavily on the epilepsy patient. So yes, brain surgery is also a scary proposition. But what I try to do is is tell them the facts. ⁓ tell them the ⁓ the the risk profile of this, the safety profile of this. Epilepsy surgery is changing. We're doing a lot more ⁓ minimally invasive procedures as you alluded to. So I think when you approach it that way to go to the root cause and try to give that in a balance for the surgery, it it really helps patients navigate that. speaker-0: So we talked a little bit about your work in the device-based neuroelectronics research lab. What are you working on right now that excites you the most? speaker-1: Yeah. Well, you know, it gets back to something I I talked about earlier is to trying to purpose engineer brain computer interfaces. And I use that in a broad term from both diagnostic brain computer interfaces and therapeutic interfaces to d be purpose built for the the minimally invasive sort of profile that we need to treat the brain condition. So for us, we're laser focused on epilepsy right now. Can we transform neuromodulation and deep brain stimulation for epilepsy? into a curative therapy. ⁓ is that by programming the device more precisely or in a EEG biomarker-driven fashion? Is it combining it with a purpose-filled ⁓ medication or electrically uncaged medication? There's a multitude of different domains there, but really starting and thinking about the least complex, the least invasive device to have the maximum impact is our guiding principle. We could talk for hours about our our our specifics here. We're interested in pattern stimulation, how the brain responds to that. Most brain stimulation right now is like the rhythm of a ⁓ of a of a drum, right? ⁓ more or less a a a constant rhythm with maybe some breaks in between. But the brain doesn't fire like that in most cases. And we know that rhythmic stimulation can actually entrain and strengthen some abnormal connections to the brain. So we're looking at non-periodic, non-rhythmic, so-called the jazz drummer, if you will. ⁓ stimulation to try to break down some of these abnormally entrained neural circuits that have a ⁓ that have a ⁓ role in epilepsy and movement disorders and other conditions. speaker-0: Fascinating. And and when you look at marrying that with some of the minimally invasive techniques that you're exploring, what are what are some of the techniques that you're you're looking at evaluating? speaker-1: Well, we specifically have a ⁓ a deep interest in subscalp EEG, sometimes called subgaleo EEG. EEG electroencephalography has been around for greater than a hundred years now. ⁓ in really there's a multitude of formats of EEG, and we've even covered them this hour, from micro scale single, multi-neuron recordings to macro scale brain oscillations and brain potentials recorded outside of the skull. That's our classic scalp EEG. And that's what oftentimes brain wearables use is scalpy EG. And there's many layers, no pun intended, between outside of the skull and the deep structures of the brain. So when we think about those layers and spaces, we're interested in in spaces which have that balance of of the adequate precision of the brain recording and the least invasiveness. So a subscalp device which lives outside the skull and underneath the scalp is a place where we can record EEG from the brain with high fidelity. ⁓ depending on where it is with lower ⁓ muscle artifact and other things of that nature. And also this place where if in ten years you need a new device or an upgrade or a modular improvement, it doesn't require revision brain surgery to do that. It requires an outpatient procedure or scalp surgery to do that. So that's what our group has been focused on in terms of device development. speaker-0: Interesting. So you're you're below the scalp but above the skull essentially. That that's fantastic. And do you find that there are certain materials or properties that are advancing that are assisting with threading that needle? speaker-1: So there certainly are are ways that we're ⁓ at least our group is thinking about putting these devices under the scalp, ways that we can dissect that space and visualize that space and sort of unfurl or unfold to deliver an electrode. I think what you're also alluding to is the material science here and the engineering of the electrode arrays. And again, it gets back to the basic principles what are we treating? What's the biology? What's the minimum complexity of brain information? meaning the signals from the brain that I can use to decode that state and act on it. And then we need to purpose build electrode rays and and sort of delivery mechanisms that address that specific need. So that's what we're going after. Like you alluded to earlier, there's a lot of excitement about high channel count and how many channels can you get on a device. And for the most part, there may be indications we need that. We're not taking that approach. We're really trying to take a more reductionist approach. What's the minimum information that we need? And it may be a high channel count system or it may not be. So we're trying to take that first and purpose building the electrodes and devices around around that clinical need. speaker-0: Right. And I can imagine because you're seeing patients as well that these two worlds inform each other. In other words, your your lab is giving you some perspectives for when you see patients and there might be patients that you're seeing that's informing your work in the lab. And has that been something that's really driven this philosophy that that you speak of? speaker-1: Yeah, it it I mean it and it's also just how what we would want, right? You know, if if ⁓ if we were afflicted with this condition or our family was or our loved ones were, we would want this. We would want the safest, most minimally invasive, highest efficacy device. So that from ⁓ I guess a moral or ethical or existential driver, that that's what I think about. But the energizing part that comes from the patients. You know, these are exciting technologies. We you know, a lot of us in this field got into this because we love working with technology. But that's not enough for me. I l I love actually using the technology to treat people. And when you see patients day in and day out that are that are having this need, you can't help but sort of get itchy. ⁓ y you gotta work on these questions. I don't there's not really an alternative. ⁓ we have to move the field forward. The patients are looking for it. When you start to tell them about the work you're doing to drive this forward, ⁓ almost uniformly, they're also excited. They wanna hear the details, they wanna They wanna the to learn the direction the field is going. They wanna hear the hope and optimism that might apply to their condition into the future. So that that's what keeps me going. speaker-0: Yeah, and it's interesting because I think the ⁓ the more that you work in the field and and you speak to patients, the reduction of burden, turning down the volume, the improvement of quality of life can have such a profound impact. And a lot of times, at least historically in medicine, we've tended to think about improvement of survival, reduction of mortality, but the improvement of quality of life can be just so profound and impactful to to patients and I think it's something we've been exploring more and more in neuromodulation and we're even starting to see that line between therapeutic devices and I'll call them lifestyle devices starting to blur. For example, you could imagine device for obstructive sleep apnea versus maybe one for urinary incontinence. How do you feel about this blurring of the lines? Is this a a good thing for the field? speaker-1: Well, I think it comes back to what the impact and the level of impact is to the therapy on the patient, right? And I think there has to be sort of a reckoning and a scaling of impact, invasiveness, and safety. ⁓ so when something is invasive into the brain, ⁓ maybe a a so-called non-lifestyle device, then what there needs to be appropriately very high safety and efficacy thresholds to me. I think we're we we almost universally agree upon that. Where there's probably less agreement are the shades of gray in between, or devices where there is clinical impact, but it's more minimal, but it may also be a lot less risky and less invasive to the patient. Where is that line? And when do we let patients decide where that line is for themselves? And that's the slippery slope that I think you're alluding to, Amari, is that where where is that line? Where's the degree of responsibility and risk that patients can load onto themselves? For some of these non-invasive devices. I think even just in this for this year, right, we have an FD-approved transcranial stimulation device at home for depression, right? And that got a lot of excitement. Although potentially ⁓ there may be new therapies down the line that could have a bigger impact ⁓ with with intracranial neuromodulation. Maybe a patient would rather start with that or just keep with that because the downsides in terms of the risk may be manifold magnitudes less than the invasive implant. So everyone has to make that decision for themselves. But I think we have to be careful as an industry that's developing these devices, regulatory bodies, to not close the door on patients that say, I I I wanna, I wanna use this device even for a moderate impact because it's very, very safe to do so. And I I think we need to keep our eye on the ball with that, that not every therapy, even within the same disease vertical, is gonna have the same level of efficacy, but there certainly is gonna be different risk profiles. ⁓ so that's how I sort of think about that space. And That's sort of my answer too when patients ask me about trying things that are non invasive with basically no risk, although the clinical data may be poor. You know, I think when that's safe and there's good safety data that it's worth a try. ⁓ and that's basically what I tell my patients in those cases. speaker-0: Yeah, certainly. Safe safety is kind of that that first bar. And if there's zero risk, the evidence required to support it might be might be lower. And it's fascinating to me because we've seen neuromodulation now for many, many years being used to to address an array of pain conditions. So implant ISIS for pain essentially. And we're talking about physical pain in that context, but now we're starting to see exploration. in areas that are more psychiatric in nature. You mentioned depression. So you you could call that, you know, almost a different type of pain. And I think as a society, as we start to understand these conditions, physical pain and psychiatric pain may be no different in terms of magnitude in the profound nature of on a patient. So so therefore, if you have safety shown, you know, the the ability to impact and address those things either in a way Or an implantable, it it feels as though there's at least ⁓ from a hypothesis standpoint, you know, hypothesis generating in terms of its relevance. speaker-1: Yeah, I I I agree with that and ⁓ and there's certainly folks that are thinking deeply about sort of we're talking about the maybe ⁓ the endpoints that may be relevant for psychiatric conditions, conditions where ⁓ the the really the state that's being treated is is non ⁓ is internal and hard to objectively measure. There I don't think there's a silver bullet in that space. It it it is a complexity and in how we do that for depression, how we do that for loss of controlled eating disorder, pain. Obviously, there's a huge, huge societal need for better treatments of pain, right? Opioid epidemic, lack of pharmacologic interventions that don't ⁓ develop ⁓ tolerance and resistance in patients. So I think that there there certainly is a is a large clinical need there. ⁓ but the endpoint construction is a big challenge. Frankly, the other thing that I think about in the neuro ⁓ neurologic disease verticals. Is is preparing neuromodulation for the impending wave of cell and gene therapies that may be disease modifying. I think us as a field of advice folks, we need to be aware of that, because that could very rapidly change the relative efficacy of our therapies with a whole new class of disease modifying therapies. So I think it's important that we think about how our therapies could be used both synergistically and in combination with cell and gene therapies. How do we deliver cell in gene therapies to patients who have in situ neuromodulation devices where there's been a ceiling of the effect? I I you know, I think this is something that we got to think about a little bit as a field, you know, imaging compatibility, right? Sometimes we think of that as a on the wish list versus ⁓ having that from day one in terms of high field MRIs now and and CT imaging. So I think the convergence of cell and gene therapy and implanted devices is another blind spot. The that we have to think about as a device field. speaker-0: Yeah, I love that characterization. Oftentimes we think of these different domains as being competing, but they actually can be complementary. And if we think about them deeply and you think about sequencing, the impact to patients can be truly, truly profound. So I I love the complementary nature and staying abreast of advances on both sides of the ledger. So you've moved from pursuing computing prizes to cancer research to brain surgery. Is there a particular problem that you are currently most hungry to solve? speaker-1: Well, I think it's it's really trying to get these neuromodulation therapies across the finish line, so to speak. Get them into patients, build companies and devices that have a sustainable ⁓ you know, business behind them, right? That these devices can survive in and actually get to patients. And certainly you don't learn that in medical school or neurosurgery residency, but you can't sort of think of that as a as a, you know, someone else is gonna sort that out for me or I'll let the business folks tackle that one. I think you got to think about how this fits into the current ecosystem up up front, right? Is there a re reimbursement channel? ⁓ I think discovery science is is amazing. I love doing it. I love those aha moments. ⁓ but I think as much ⁓ at least what gets me up in the morning is doing those aha moments, but trying to put that in a context and push the limits of what is actually financially feasible in a new device in the current healthcare system, right? If we divide something that can't that only, you know, 0.01% of people can afford or can be delivered to. It's very fascinating and it can be helpful for that 0.01%. But how do you devo design a device that could be rolled out to millions of patients? ⁓ it can be done in a sustainable fashion, allows you to build a company that then can generate the next generation device that's even more efficient, lower cost. So I think that's the that is a really hard challenge. ⁓ and and is a whole nother skill set than the science side of things. And So I love partnering with experts in that space and trying to tackle to ⁓ tackle that aspect of of device design as well. speaker-0: Yeah, and it's a really great view. It's a it's a broad view, but it's an important one. If you think back to your metaphor of turning down the volume, reducing the burden of these conditions, in many cases it can enable patients to get back to work to be productive. So there's an economic societal benefit ⁓ to these. It's on the industry side to be able to support that with evidence that makes it very clear. But I think there's definitely arguments to be had. But to your point, Ensuring that these technologies are accessible for all, the many and not just the few, I think is a critical aspect of of what we're trying to do. speaker-1: And to do that, I think you've got to think from the beginning about the scale of the device, the complexity of the surgery, the care, ⁓ the care ⁓ context or actually the physical location, right, that where a patient will get a device. You know, obviously we we work day in and day out in modern operating rooms at large tertiary academic centers and at the Mayo Clinic, we have the latest and greatest technology. How will we do that going forward when all of a sudden a million patients or five million patients need access to this therapy? that's very complex to implant. How do we do that safely, reliably, across large scale, I think is an important problem. Again, you can't just build it and think someone else will fix it. I think you gotta think about that all the way along. speaker-0: Yeah. Yeah. And so it's great that you're having this focus on getting these therapies over the finish line for the benefit of patients, because we truly are seeing an explosion in innovation right now. And as we do that, if you were to paint a picture, let's call it an optimistic picture, the future of neuromodulation and BCI, let's say ten years from now, what could that look like? speaker-1: Yeah, I think you're gonna see BCIs at different scales. ⁓ again, getting back to what we're talking about before, from the least invasive scale, consumer grade diagnostic BCI that helps dru ⁓ guide ⁓ drug response and drug selection that interfaces with the clinician to ever complex, you know, sort of very focal BCIs like we see in the in the motor space or in the speech re ⁓ rest restoration space. I think those are gonna get even more fluid and delivered to more patients. So I think That's the future. There's going to be multiple scales of both diagnostic, therapeutic, and then combined diagnostic and therapeutic BCI devices across a whole level of invasiveness. ⁓ so I I think there's a lot of room for people to coexist in in this space. ⁓ I think that, you know, the blind spots are how does this interface with a disruptive cellar gene therapy that may be curative or ⁓ very highly disease modifying, right? I think that's a blind spot to think about. I think we got to think about the reimbursement channels here and also maybe high-touch devices that need a lot of training, software on a phone or a computer, ⁓ subscription-based models for certain devices. Is that on the healthcare system and insurance? Or is that ⁓ a feature that then a person pays for, right? Like we now might pay for ⁓ access to our favorite LLMs, for example. So I think those border lines between lifestyle, ⁓ devices, insurance coverage. We got to start to think about that and navigate that now. So I want to end with the blue sky version. I think that there's a role for all those different devices to think about. And I'm hopeful that people that are getting into this field want to tackle there's there's room for everyone. There's a lot of things to tackle. It's not all signal processing, although that's really exciting, or materials engineering, but even economics, ethics, delivery science, usability, user interface. The the there's so much to be done in the neurotech space and it is the final frontier. So if you're listening to this, you know, don't wait till tomorrow. You know, start doing these things today. speaker-0: Yeah, and for those who are listening to this and are motivated, excited and want to work at on this final frontier of brain science and technology, what advice would you give to them? speaker-1: Yeah. Well, there's so many ways to get involved ⁓ from both the academic perspective, but then also in the industry perspective. And then also on the patient side, right? Even helping patients communicate the needs that they have and patient advocacy, right? There there's many different faces to the to this space. So I'd say you you gravitate towards the the faces that that that ⁓ excite you. If it's building the technology, then it makes sense to get a very deep knowledge of the math and science behind that, you know, quantitative approaches ⁓ in that area, engineering coursework, math coursework, computer science coursework, biology, if that excites you. ⁓ if it's the industry side and the delivery end, then having the understanding of the vocabulary of that, but then pairing that with the business education in both an academic sense or real world sense, I think is going to be important. If it's the patient advocacy side, it's It's again understanding the the granular vocabulary, but then also learning how to describe these needs in an approachable fashion that both clinicians, payers, and industry understands, right? So however you want to address these problems, there's a different approach. But I'd say start doing, you know, start doing something tomorrow. ⁓ you know, a lot of ⁓ research scientists ⁓ have internships in their lab, same thing for industry, same thing for clinicians doing this and And reach out to the folks that you're excited by the work that they're doing, you know, nine times out of ten, they'll respond to you and they'll either have an opportunity for you or they'll guide you to an opportunity that can get you that experience. speaker-0: Fantastic. Great. Well, this has just been a a tremendous conversation. So much insight, perspective, optimism, and also I think great direction for for where this field is is going. Really have appreciated your time and being able to talk about your career and the things you're working on and couldn't be more excited to see what comes out of out of the lab and out of also out of your clinic. speaker-1: Well, Mari, I really enjoyed the conversation. It was energizing. I think we covered a lot of interesting ideas and topics and set the table for the things that we need to work on together as we move the field forward. So ⁓ I I look forward to hearing the progress that you guys make on the engineering side and how to power these devices. And I think it'll be a very exciting future for the sake of the patients. speaker-0: Yeah, we definitely agree on that, and we look forward to seeing the advances you make at the at the clinic. Very, very exciting. So thanks to all of you for joining us on Powering the Future Within. If this conversation inspired you, follow the show and share it with your MedTech community. I'm Omari Bachknight. Stay inspired and keep innovating.